RE: One liner17 Nov 2019 09:20
Agree Aim. All these newbies who came onboard with the Time's article probably don't realise that there is a £51m R&D milestone agreement with 20% royalties on future sales. Just from this deal, at current SP this is already de-risked for me as most new Pharma's would just have one of these deals to grow off. This make NXP001 less of a worry when people are de-ramping, as Ebers in my mind could be worth more. Obviously NXP002 will be the one that will send us into the stratosphere mind!